重组Anti-PLK1 (phospho T210)抗体[EPNCIR167]
Anti-PLK1 (phospho T210) antibody [EPNCIR167]
- RabMAb
- Recombinant
- 了解详情
Be the first to review this product! Submit a review
|
(24 Publications)
Rabbit Recombinant Monoclonal PLK1 phospho T210 antibody. Suitable for Dot, WB, IHC-P and reacts with Human, Mouse samples. Cited in 24 publications.
查看别名
PLK, PLK1, Serine/threonine-protein kinase PLK1, Polo-like kinase 1, Serine/threonine-protein kinase 13, PLK-1, STPK13
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling PLK1 with ab155095, unpurified, at 1/100 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Immunohistochemical analysis of paraffin embedded Human placenta tissue using ab155095, unpurified, showing +ve staining.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Immunohistochemical analysis of paraffin embedded Human thyroid gland carcinoma tissue using ab155095, unpurified, showing +ve staining.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
ab155095 staining PLK1 (phospho T210) in Human colon tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed and paraffin-embedded, antigen retrieval was by heat mediation in Tris/EDTA buffer pH9. Samples were incubated with primary antibody (1/500). An undiluted HRP-conjugated anti-rabbit IgG was used as the secondary antibody. Tissue counterstained with Hematoxylin. PBS was used in the negative control rather than the Primary antibody.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Immunohistochemical analysis of paraffin-embedded Human gastroic carcinoma tissue labeling PLK1 with ab155095, unpurified, at 1/100 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Immunohistochemical analysis of paraffin embedded Human cervical carcinoma tissue using ab155095, unpurified, showing +ve staining.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB
Unknown
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
All lanes:
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution
Lane 1:
HeLa cell lysate, untreated at 10 µg
Lane 2:
HeLa cell lysate, treated with calyculin A at 10 µg
Secondary
All lanes:
Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 68 kDa
false
- WB
Lab
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
antibody used for ab155095 is purified batch.
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
All lanes:
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution
Lane 1:
Hela (Human cervix adenocarcinoma epithelial cell) whole cell lysates at 15 µg
Lane 2:
Hela (Human cervix adenocarcinoma epithelial cell) treated with thymidine (2mM, 16 h) then with nocodazole (10nM, 24h) Whole cell lysates at 15 µg
Lane 3:
Hela (Human cervix adenocarcinoma epithelial cell) treated with thymidine (2mM, 16 h) then with nocodazole (10nM, 24h) Whole cell lysates, then the membrane was incubated with phosphatase at 15 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 68 kDa
Observed band size: 68 kDa
false
Exposure time: 10s
- WB
Lab
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Blocking buffer and concentration : 5% NFDM/TBST. Diluting buffer and concentration : 5% NFDM/TBST. Exposure Time : Lane 1-2 : 40 seconds, Lane 3 : 3 seconds and Lane 4 : 180 seconds. ab181602 was used as a loading control.
All lanes:
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) (RIPA) whole cell lysate at 20 µg
Lane 2:
NIH/3T3 (Mouse embryonic fibroblast) (RIPA) whole cell lysate at 20 µg
Lane 3:
Mouse testis (RIPA) lysate at 20 µg
Lane 4:
Mouse colon (RIPA) lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 68 kDa
Observed band size: 68 kDa
false
- WB
Supplier Data
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
All lanes:
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) at 1/1000 dilution
Lane 1:
HeLa cell lysate at 10 µg
Lane 2:
HeLa cell lysate post treatment with Nocodazole at 10 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), HRP-conjugated at 1/1000 dilution
Predicted band size: 68 kDa
false
- Dot
Lab
Dot Blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
Anti-PLK1 (phospho T210) antibody [EPNCIR167] (ab155095) Dot Blot. Primary ab dilution 1 : 1000, Secondary ab description and code (ab id)Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051), Secondary ab dilution 1 : 100,000. Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM /TBST. Lane 1 : PLK1 (pT210) phospho peptide, Lane 2 : PLK1 non-phospho peptide, Exposure time 10 seconds. Note : antibody used for ab155095 is purified batch.
- WB
CiteAb
Western blot - Anti-PLK1 (phospho T210) antibody [EPNCIR167] (AB155095)
PLK1 (phospho T210) western blot using anti-PLK1 (phospho T210) antibody [EPNCIR167] ab155095. Publication image and figure legend from Liccardi, G., Ramos Garcia, L., et al., 2019, Mol Cell, PubMed 30598363.
ab155095 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab155095 please see the product overview.
RIPK1 Negatively Regulates PLK1(A) Schematic representation of RIPK1- and Casp8-mediated regulation of PLK1.(B) Immunoblots of primary intestinal organoids from two Ripk1fl/fl,IEC-creERTM animals. Organoids were treated with ETOH (vehicle control) or 4-OHT, synchronized with CDK1i, and released into media. Cells were lysed and analyzed by immunoblot with the indicated antibodies.(C) In situ PLA detection of PLK1 and RIPK1 in HT1080 cells, following Casp8 or Plk1 siRNA. Green dots indicate PLA signals between PLK1 and RIPK1. Graph shows quantifications of RIPK1/PLK1 PLA speckles (mean ± SD). 15 cells were counted for each condition. Scale bars : 10 μm.(D and E) In vitro cleavage assay. Purified HA-tagged PLK1 construct and recombinant Casp8 were incubated for 1 h. Immunoblots analysis using the indicated antibodies is shown.(F) HT1080 cells were synchronized with CDK1i and released in media containing the indicated drugs. Lysates from asynchronous or synchronized HT1080 cells were immunoprecipitated with anti-Casp8 antibody. Immunoblot analysis using the indicated antibodies is shown.(G) In situ PLA detection of Casp8/RIPK1 in CDK1i-synchronized and released HT1080 cells treated with the indicated agents. Green dots indicate PLA speckles. Scale bars : 10 μm.
false
不同偶联物与剂型 (8)
-
Anti-PLK1 (phospho T210) antibody [EPNCIR167] - BSA and Azide free
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
578 PE
PE Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
660 APC
APC Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-PLK1 (phospho T210) antibody [EPNCIR167]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-PLK1 (phospho T210) antibody [EPNCIR167]
反应性数据
产品详情
This antibody was developed as part of a collaboration between the National Cancer Institute's Center for Cancer Research and the lab of Kyung Lee. View antibodies from NCI Center for Cancer Research Collaboration.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please contact us for more information.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存条件
推荐的长期储存条件
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (24)
Recent publications for all applications. Explore the full list and refine your search
Cell death & disease 16:673 PubMed41022752
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 16:374 PubMed40355412
2025
Applications
Unspecified application
Species
Unspecified reactive species
Biomedicines 13: PubMed39857637
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer research communications 5:253-266 PubMed39831777
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell proliferation 57:e13590 PubMed38084791
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of biochemical and molecular toxicology 38:e23590 PubMed38037286
2023
Applications
Unspecified application
Species
Unspecified reactive species
Nature chemical biology 20:566-576 PubMed37945898
2023
Applications
Unspecified application
Species
Unspecified reactive species
American journal of reproductive immunology (New York, N.Y. : 1989) 90:e13793 PubMed37881124
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 14:695 PubMed37872147
2023
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of cell biology 222: PubMed36897279
2023
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com